Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Adverum Biotechnologies Inc
ADVM | US
8.26
USD-0.22
-2.59%
ADVM | US
About Adverum Biotechnologies Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
8.26
Open
8.44
High
8.53
Low
8.18
Adverum Biotechnologies Inc. a clinical-stage company develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022) a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin) a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek Inc. The company was formerly known as Avalanche Biotechnologies Inc. and changed its name to Adverum Biotechnologies Inc. in May 2016. Adverum Biotechnologies Inc. was incorporated in 2006 and is headquartered in Redwood City California.
View LessADVM | US
Risk
69.9
Sharpe
-0.19
Luna's Score
40/100
Recommendation
Sell
Luna says (ADVM | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
47.5%1 month
69.9%3 months
59.2%6 months
62.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.00
Debt to equity
0.44
Debt to assets
0.29
Ent. to EBITDA
0.10
Ent. to rev.
3.70K
PEG
-
Other Fundamentals
EBITDA
-103.71M
MarketCap
171.82M
MarketCap(USD)
171.82M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-70.00
Ret. on equity
-66.76
Short ratio
9.71
Short perc.
7.17
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.36
Range1M
2.04
Range3M
2.19
Volumes: Market Activity
Rel. volume
0.92
Price X volume
1.75M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.10 | - | Cheaper |
| Ent. to Revenue | 3,700.64 | - | Par |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.00 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 59.20 | - | Par |
| Debt to Equity | 0.44 | -1.23 | Expensive |
| Debt to Assets | 0.29 | 0.25 | Par |
| Market Cap | 171.82M | - | Emerging |
